We offer more than just comprehensive genetic screenings, such as the LABOGenetics XXL packages for dogs and cats. Our portfolio also includes breed-specific packages, as well as nearly all genetic tests, which are also available as individual tests.

Individual tests are particularly useful when an animal needs to be screened specifically for a certain hereditary disease or coat trait. This applies, for example, to symptomatic animals in which specific hereditary diseases need to be confirmed or ruled out, as well as to breeding animals that have not yet undergone a newly available genetic test. In some cases, it is even possible to analyze sample material that has already been stored, without the need to resubmit it.

With our individual tests, you’ll benefit from an affordable price and a particularly short testing time. Our range of individual tests is continually expanding and is always based on the latest scientific findings.

In addition, we are constantly making improvements to our existing tests. Among other things, this allows us to significantly reduce test runtimes even further. Current examples of this include tests for clopidogrel efficacy in cats, as well as tests for the MDR1 gene variant, CEA, and prcd-PRA in dogs.

This is how we ensure that you always benefit from fast and reliable genetic testing and that you can find the right test format for every question. If you’re still unsure which test is right for you, we’d be happy to recommend our decision-making guide to help you choose the right service:

Our popular breed packages are getting some new additions: packages for the Australian Kelpie and Cane Corso Italiano breeds are now available. The breed packages can be used to identify the relevant breed-specific hereditary diseases and coat characteristics. This provides a solid foundation for forward-looking breeding planning.

Cane Corso Italiano Package

Includes the following tests:
Degenerative myelopathy (DM Exon 2), dental-skeletal-retinal anomaly (DSRA), canine multifocal retinopathy (CMR1), hyperuricosuria (SLC), and neuronal ceroid lipofuscinosis (NCL)

Test duration: 7–14 business days
The package costs EUR 110.00 incl. VAT

Intestinal lipid malabsorption is a hereditary metabolic disorder in the Australian Kelpie in which the absorption and processing of dietary fats are impaired.

Affected dogs do not thrive even as puppies, remain significantly smaller than their littermates, and often have greasy, light-colored stools and a shaggy coat. The cause is a variant in the ACSL5 gene, which plays a key role in the absorption and metabolism of long-chain fatty acids in the small intestine. As people get older, the symptoms may subside. Nevertheless, the animals are generally smaller, and they often continue to have an intolerance to high-fat food.

Genetic testing is particularly important for breeders, as it allows them to reliably identify carrier animals and make targeted breeding decisions.

With LABOGenetics XXL Dog, breeders and dog owners get a comprehensive overview of their dog’s genetics. The screening tests for over 340 genetic variants and provides information on possible hereditary diseases, genetic risk factors, and coat colors and characteristics. This makes it possible to identify health risks early on and make informed breeding decisions.

Now LABOGenetics XXL Dog is even more user-friendly and practical:

New Symbols for Symptom Complexes
In the test results, small symbols appear after each test to indicate the corresponding set of symptoms. This makes it easier to interpret the results more quickly.

Two Findings for Greater Clarity
Effective immediately, you will receive two documents: the complete comprehensive report with all test results, and a concise specialized report covering breed-specific tests, coat colors, and any additional tests you requested.

New filter feature on the website
On the LABOGenetics XXL Dog information page, all tests included in the screening can now be filtered by dog breed and/or set of symptoms. This ensures that the relevant tests are displayed.

IGS is an inherited disorder that affects the absorption of vitamin B12. The resulting deficiency impairs blood formation and can lead to anemia as well as neurological deficits. The first symptoms usually appear during puppyhood, between about 6 and 12 weeks of age. Typical symptoms include insufficient weight gain and growth retardation, fatigue, loss of appetite, anemia, and general weakness.

Effective immediately, the IGS genetic test is available for Australian Shepherds and Miniature American Shepherds, in addition to Border Collies, Beagles, and Komondors. For these two breeds, testing is conducted for an autosomal recessive variant in the so-called AMN gene.

Early diagnosis allows affected dogs to maintain a good quality of life through lifelong vitamin B12 supplementation. Genetic testing also helps prevent the birth of affected puppies through targeted breeding planning.

Primary hyperparathyroidism (PHPT) is a hereditary disease in which the regulation of calcium levels in the body is disturbed. Possible consequences are an increasing weakening of the bones, kidney problems and even kidney failure as well as other metabolic disorders.

A variant in the SIRT6 gene was found in the Wolfspitz/Keeshond that is associated with the disease. This is inherited in an autosomal dominant manner. The late onset of the disease is particularly challenging for breeders, as the symptoms of PHPT usually only become apparent after the age of 8 and therefore often at a time when the dogs have already been used for breeding. The genetic test enables early identification of affected animals and supports breeders and owners in responsible breeding selection and prevention.

The genetic test for Adult Onset Neuropathy (AON) is now available again! The test is carried out by a partner laboratory and is offered for the English Cocker Spaniel and Field Spaniel breeds.

AON is a hereditary disease whose symptoms are similar to those of degenerative myelopathy (DM). The first symptoms typically appear at the age of 7.5 to 9 years and are characterized by weakness of the hind legs, resulting in an uncoordinated gait and a wide-legged stance. As the disease progresses, the weakness spreads to the front legs and can eventually lead to difficulty swallowing.

Arterial thromboembolism (ATE) is a serious and often life-threatening complication in cats with hypertrophic cardiomyopathy (HCM) or other heart diseases. It occurs when a blood clot (thrombus) blocks an artery and thus interrupts the flow of blood to organs or limbs. The consequences are often severe tissue damage or infarctions.

Hypertrophic cardiomyopathy (HCM) is a genetic heart disease in which there is an abnormal thickening of the left ventricle. As this ventricle is responsible for the blood supply to the entire body, HCM can significantly impair the heart’s pumping capacity. This can result in a reduced oxygen supply to the organs.

The disease can have serious consequences, including cardiac arrhythmia, abnormal blood clotting (risk of thrombosis) and heart failure. The clinical symptoms are highly variable and range from reduced exercise tolerance and breathing difficulties to fainting or collapse.

A genetic variant in the TNNI3 gene associated with HCM has been identified in a family of Golden Retrievers. The disease is believed to be inherited in an autosomal recessive manner and, in the worst case, can lead to sudden cardiac death.

Cerebellar abiotrophy (CA) is a hereditary neurological disorder that causes changes in the cerebellum, which is particularly responsible for movement coordination and balance.

Two genetic risk markers associated with CA have been identified in the Australian Kelpie. Clinical manifestations of the disease include pronounced ataxia, head tremor, a wide-legged stance of the hind limbs and a conspicuous gait pattern in which the legs are raised excessively when walking.

One variant affects the LINGO3 gene and is inherited in an autosomal recessive manner with incomplete penetrance. The first symptoms of this variant can appear as early as 4 to 10 weeks of age, although the severity of the symptoms can vary greatly. The second variant in the VPM1 gene shows a later onset of the disease (from about 4-6 months or older) and follows an autosomal recessive inheritance with complete penetrance.
Genetic testing makes it possible to identify carrier animals at an early stage and make well-founded breeding decisions.